BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:"Exploiting ASS1 deficiency in the treatment of mesothelioma" - Dr
  Peter Szlosarek\, Cancer Research UK Clinician Scientist\, Senior Lecture
 r and Honorary Consultant in Medical Oncology\, Barts and The London
DTSTART:20120327T103000Z
DTEND:20120327T120000Z
UID:TALK35452@talks.cam.ac.uk
CONTACT:Mala Jayasundera
DESCRIPTION:Malignant pleural mesothelioma is an intractable asbestos-rela
 ted cancer with a median survival of less than 12 months and an estimated 
 total economic burden running into several billion pounds. We have identif
 ied epigenetic loss of the rate-limiting enzyme for arginine synthesis arg
 ininosuccinate synthetase (ASS1) in mesothelioma cells revealing a novel A
 chilles’ heel using arginine deprivation. A CRUK-funded randomized phase
  2 trial of the arginine-depleting agent ADI-PEG20 and best supportive car
 e (Polaris Group\, US) versus best supportive care alone is underway in pa
 tients with ASS1-deficient mesothelioma in the UK. Current preclinical and
  clinical work will be discussed with an emphasis on developing arginine d
 eprivation as a novel therapeutic option for patients with mesothelioma an
 d other ASS1-deficient cancers.\n\n
LOCATION:Seminar Room 2\, Clinical School\, Addenbrooke’s
END:VEVENT
END:VCALENDAR